1. Home
  2. Nation
  3. Phase III trial of Bharat Biotech’s COVID-19 nasal vaccine completed, may be launched soon

Phase III trial of Bharat Biotech’s COVID-19 nasal vaccine completed, may be launched soon

By Ruchi Upadhyay 
Updated Date

Paris: Bharat Biotech Chairman and Managing Director Krishna Ella said on Saturday that the Phase III trial of the COVID-19 nasal vaccine has been completed and the company will submit its data to the Drugs Controller General of India (DCGI) next month. In an exclusive interview, Dr. Ella said, “We have just completed a clinical trial, a data analysis is underway, next month, we will submit the data to the regulatory agency. If all goes well, then We will get permission and the vaccine will be launched. This will be the world’s first clinically proven nasal COVID-19 vaccine.”

Also Read :- Omicron's new XBB sub-variant knocks in India, so far 71 cases found in 4 states

Dr. Ella was in Paris as a speaker at Viva Technology 2022, where India was declared the Country of the Year. It is to be known that in January this year, the Drug Controller of India had given permission to Bharat Biotech to conduct a standalone phase III trial on its nasal corona vaccine. On the booster dose of Kovid-19, Dr. Ella said that those who have taken the second dose must definitely take the booster dose.

Also Read :- India@75: Bharat Biotech finishes clinical trials for BBV154 intranasal COVID-19 vaccine; Calls it safe

He said, “A booster dose of a vaccine gives immunity. I always say that a booster dose is a miracle dose for every vaccination. Even in the first children, two doses do not give much immunity, but the third dose in children Gives an amazing response to . It has to be controlled more intelligently.”

Further reading:
For the latest news and reviews, follow us on Facebook, YouTube and Twitter पर फॉलो करे...